Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 17, 2025 07:00 ET | Source: Unicycive Therapeutics, Inc.

Unicycive Therapeutics, Inc. Announces Reverse Stock Split

LOS ALTOS, Calif., June 17, 2025 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (NASDAQ: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today...
June 10, 2025 06:00 ET | Source: Unicycive Therapeutics, Inc.

Unicycive Provides Update on New Drug Application for Oxylanthanum Carbonate to Treat Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis

- The U.S. Food and Drug Administration (FDA) identified deficiencies at a third-party manufacturing vendor - FDA to provide final decision by PDUFA action date of June 28, 2025 LOS ALTOS,...
May 22, 2025 07:00 ET | Source: Unicycive Therapeutics, Inc.

Unicycive Therapeutics to Present at Upcoming Investor Conferences

LOS ALTOS, Calif., May 22, 2025 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today...
May 21, 2025 07:00 ET | Source: Unicycive Therapeutics, Inc.

Unicycive Therapeutics Announces Time Change for 2025 Annual Meeting of Stockholders

LOS ALTOS, Calif., May 21, 2025 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (NASDAQ: UNCY) (“Unicycive” or the “Company”), a clinical stage biotechnology company developing therapies for...
May 14, 2025 07:15 ET | Source: Unicycive Therapeutics, Inc.

Unicycive Therapeutics Announces First Quarter 2025 Financial Results and Provides Business Update

- Oxylanthanum carbonate (OLC) New Drug Application (NDA) for hyperphosphatemia in chronic kidney disease patients on dialysis under review by FDA with PDUFA target action date of June 28, 2025;...
April 10, 2025 08:00 ET | Source: Unicycive Therapeutics, Inc.

Unicycive Presents New Patient-Level Data Underscoring Challenges Faced with Current Phosphate Binders and Highlighting the Potential of Oxylanthanum Carbonate to Address Barriers to Adherence for Patients with Hyperphosphatemia on Dialysis

– Patient-reported outcomes from Phase 2 trial of oxylanthanum carbonate (OLC) demonstrate high patient satisfaction with OLC compared to their prior phosphate lowering therapy – – Findings from a...
April 01, 2025 07:00 ET | Source: Unicycive Therapeutics, Inc.

Unicycive Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference

LOS ALTOS, Calif., April 01, 2025 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today...
March 31, 2025 07:00 ET | Source: Unicycive Therapeutics, Inc.

Unicycive Therapeutics Announces Full Year 2024 Financial Results and Provides Business Update

- Oxylanthanum carbonate (OLC) New Drug Application for hyperphosphatemia in chronic kidney disease patients on dialysis under review by the FDA with a PDUFA target action date of June 28, 2025 ...
March 13, 2025 07:00 ET | Source: Unicycive Therapeutics, Inc.

Unicycive to Highlight Patient Reported Outcomes Data at Upcoming Medical Meetings Showing Oxylanthanum Carbonate Reduced Pill Burden and Improved Adherence in Treatment of Hyperphosphatemia

LOS ALTOS, Calif., March 13, 2025 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today...
February 20, 2025 07:00 ET | Source: Unicycive Therapeutics, Inc.

Unicycive Therapeutics Announces the Publication of Preclinical Data on Synergies Between Oxylanthanum Carbonate and Tenapanor in American Society of Nephrology Journal Kidney360

LOS ALTOS, Calif., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today...